Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.
BACKGROUND
Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy.


METHODS
The excised breast tissue and lymph nodes were examined for the presence of residual disease.


RESULTS
Pathologic complete response was observed in nine patients (90%).


CONCLUSIONS
Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.
Byrski
T
T
Pomeranian Medical University, Szczecin, Poland.
Huzarski
T
T
Dent
R
R
Gronwald
J
J
Zuziak
D
D
Cybulski
C
C
Kladny
J
J
Gorski
B
B
Lubinski
J
J
Narod
S A
SA
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D009154:Mutation; D020360:Neoadjuvant Therapy / Q000379:methods*; D044767:Ubiquitin-Protein Ligases / Q000235:genetics*
D000970:Antineoplastic Agents; C111164:BRAP protein, human; D044767:Ubiquitin-Protein Ligases; D002945:Cisplatin